DB:XRP1

Stock Analysis Report

Executive Summary

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in haematology, cardiovascular, and other rare and metabolic indications.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Silence Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XRP1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.0%

XRP1

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

730.6%

XRP1

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: XRP1 exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: XRP1 exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

XRP1IndustryMarket
7 Day7.0%-4.1%-5.7%
30 Day19.7%-8.2%-5.7%
90 Day-15.1%-2.0%-3.6%
1 Year730.6%730.6%4.0%3.7%9.3%6.1%
3 Year365.4%365.4%38.2%36.7%8.9%-0.7%
5 Year49.7%49.7%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Silence Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Silence Therapeutics undervalued compared to its fair value and its price relative to the market?

11.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: XRP1 (€5.05) is trading above our estimate of fair value (€0.54)

Significantly Below Fair Value: XRP1 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XRP1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XRP1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XRP1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XRP1 is overvalued based on its PB Ratio (11.3x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Silence Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-4.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XRP1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XRP1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XRP1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XRP1's revenue (1.4% per year) is forecast to grow slower than the German market (5.1% per year).

High Growth Revenue: XRP1's revenue (1.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XRP1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Silence Therapeutics performed over the past 5 years?

-6.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XRP1 is currently unprofitable.

Growing Profit Margin: XRP1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XRP1 is unprofitable, and losses have increased over the past 5 years at a rate of -6.9% per year.

Accelerating Growth: Unable to compare XRP1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XRP1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: XRP1 has a negative Return on Equity (-66.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Silence Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: XRP1's short term assets (£20.8M) exceed its short term liabilities (£2.9M).

Long Term Liabilities: XRP1 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: XRP1 is debt free.

Reducing Debt: XRP1 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: XRP1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if XRP1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XRP1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XRP1 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -14.8% each year.


Next Steps

Dividend

What is Silence Therapeutics's current dividend yield, its reliability and sustainability?

0.81%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XRP1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XRP1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XRP1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XRP1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XRP1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Silence Therapeutics has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Iain Ross
Executive Chairman0.8yrsno data0.032% £128.6k
Rob Quinn
CFO & Secretary1.1yrsno datano data
Barbara Ruskin
General Counsel0yrsno datano data
Linnea Elrington
VP & Head of Human Resources2.3yrsno datano data
Mark Cameron
Head of Chemistry3.8yrsno datano data
Richard Jenkins
Head of Clinical Development1.7yrsno datano data
Giles Campion
Head of R&D and Chief Medical Officer0.7yrsno datano data
John Strafford
VP & Head of Business Development0.8yrsno datano data
Jørgen Wittendorff
Head of Manufacturing0.5yrsno datano data

0.9yrs

Average Tenure

Experienced Management: XRP1's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Iain Ross
Executive Chairman0.8yrsno data0.032% £128.6k
David Lemus
Senior Independent Director0.08yrsUK£25.00k0.0072% £28.9k
Arthur Levin
Member of Scientific Advisory Board0yrsno datano data
Gordon Duff
Chairman of Scientific Advisory Board0yrsno datano data
John Porter
Member of Scientific Advisory Board0yrsno datano data
James Ede-Golightly
Non-Executive Director0.8yrsno datano data
Alistair Gray
Senior Independent Director0.2yrsUK£50.00k0.011% £44.5k
Steven Romano
Non-Executive Director0.6yrsno data0.013% £51.4k
Henry Ginsberg
Member of Scientific Advisory Board0yrsno datano data
Annemieke Aartsma-Rus
Member of Scientific Advisory Board0yrsno datano data

0.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: XRP1's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Silence Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Silence Therapeutics plc
  • Ticker: XRP1
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£336.992m
  • Listing Market Cap: UK£402.996m
  • Shares outstanding: 78.37m
  • Website: https://www.silence-therapeutics.com

Number of Employees


Location

  • Silence Therapeutics plc
  • 72 Hammersmith Road
  • London
  • Greater London
  • W14 8TH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SLNAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPApr 1995
XRP1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 1995
SLNC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 1995

Biography

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in haematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; and SLN360 for the reduction of cardiovascular risk, and prevention of heart attacks and cardiovascular diseases. Silence Therapeutics plc has a collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 20:44
End of Day Share Price2020/02/25 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.